ZK824190 hydrochloride

Cat. No.: HY-126361A

CAS No.: 2629177-12-2

Molecular Formula: $C_{22}H_{21}ClF_2N_2O_4$

Molecular Weight: 450.86

Target: Ser/Thr Protease; PAI-1

Pathway: Metabolic Enzyme/Protease

Storage: 4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (221.80 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2180 mL	11.0899 mL	22.1798 mL
	5 mM	0.4436 mL	2.2180 mL	4.4360 mL
	10 mM	0.2218 mL	1.1090 mL	2.2180 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ZK824190 hydrochloride is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC_{50}s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively[1].

In Vivo

ZK824190 (2 mg/kg; PO; Rats with EAE model) exhibits a relatively high oral availability and a moderate half time ($T_{1/2}$=2.8 h)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA